Treatment of a patient with a nodal peripheral T-cell lymphoma (angioimmunoblastic T-Cell lymphoma) with a human monoclonal antibody against the CD4 antigen (HuMax-CD4).
A patient with a CD4+ refractory peripheral T-cell lymphoma (PTL), subtype angioimmunoblastic T-cell lymphoma (AILD), was treated with a human monoclonal anti-CD4 antibody (HuMax-CD4) iv once weekly for 10 wk. Early during treatment all palpable enlarged lymph nodes disappeared. A decline of normal CD4+ T-cells in the blood mirrored the treatment effect. Shortly after stopping treatment the patient relapsed with new enlarged lymph nodes. This time no antitumor effect was seen when HuMax-CD4 treatment was reinstituted. No severe side effects were observed during the antibody treatment. This case report is the first describing that HuMax-CD4 has antilymphoma activity in PTL and is an interesting drug to study further in patients with CD4+ PTL.
Hagberg
H
H
Department of Oncology, Akademiska sjukhuset, Uppsala, Sweden. hans.hagberg@akademiska.se
Pettersson
M
M
Bjerner
T
T
Enblad
G
G
D000368:Aged; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D015704:CD4 Antigens / Q000276:immunology*; D003131:Combined Modality Therapy; D006801:Humans; D007119:Immunoblastic Lymphadenopathy / Q000276:immunology / Q000378:metabolism / Q000628:therapy*; D007167:Immunotherapy; D008198:Lymph Nodes / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D016411:Lymphoma, T-Cell, Peripheral / Q000276:immunology / Q000378:metabolism / Q000628:therapy*; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000628:therapy
D000911:Antibodies, Monoclonal; D015704:CD4 Antigens